• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Comparison of surgical modalities in the treatment of Merkel Cell Carcinoma

byAliyah KingandYuchen Dai
September 9, 2023
in Dermatology, Surgery
Reading Time: 2 mins read
Patient Basics: Basal Cell Carcinoma
Share on FacebookShare on Twitter

1. Mohs micrographic surgery was associated with significantly higher survival rates for patients with T1/T2 Merkel cell carcinoma with pathologically confirmed negative lymph nodes compared to other surgical modalities (i.e., wide local excision and narrow-margin excision).

2. Mohs micrographic surgery may be a more effective treatment for primary Merkel cell carcinoma than conventional wide-local excision.

Evidence Rating Level: 2 (Good)

Study Rundown: Merkel cell carcinoma (MCC) is a rare type of skin cancer with high mortality rates. The National Comprehensive Cancer Network guidelines state that either Mohs micrographic surgery (MMS) or wide local excision (WLE) can be used without preference. Therefore, this retrospective cohort study investigates the association between surgical excision modality (MMS, WLE, and narrow-margin excision) and patient survival for localized T1/T2 MMC confirmed by pathology. Analyses were restricted to T1/T2 tumours as they are more likely to be improved through surgery compared to later stages. Results showed that MMS was associated with significantly higher survival rates. Limitations of this study include the inability to comment on locoregional recurrence or disease-specific survival, and analyses were not controlled for patient immunosuppression. Furthermore, fewer patients were in the MMS group than the WLE group. This study also investigated hospital-based treated MCCs and did not report on treatments carried out by community-based clinics.

Click to read the study in JAMA Dermatology

Relevant Reading: Mohs surgery for early-stage Merkel cell carcinoma (MCC) achieves local control better than wide local excision ± radiation therapy with no increase in MCC-specific death

RELATED REPORTS

Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma

Patient Perspective of Opioid Pain-Control Use After Mohs Micrographic Surgery

Narrow margin excision of T1a melanoma not associated with recurrence or melanoma-specific mortality

In-Depth [retrospective cohort]: The National Cancer Database was used to identify patients with T1/T2 MCC diagnosed between January 1, 2004, and December 31, 2018. Exclusion criteria included clinically positive lymph node disease, missing clinical lymph node status data, clinically positive distant metastatic disease, and patients not treated with surgery for T1/T2 disease. This retrospective cohort study included 2,313 patients (mean [SD] age, 71 [10.6] years; 1340 [57.9%] male). MMS had the best-unadjusted survival, with mean (SE) survival rates of 87.4% (3.4%) at three years, 84.5% (3.9%) at five years, and 81.8% (4.6%) at ten years. This was compared to survival rates of WLE: 86.1% (0.9%) at three years, 76.9% (1.2%) at five years, and 60.9% (2.0%) at ten years. The survival rates were similar between WLE and narrow-margin excision (84.8% (1.4%) at three years, 78.3% (1.7%) at five years, and 60.8% (3.6%) at ten years). Furthermore, MMS was correlated to significantly improved survival when compared to WLE (hazard ratio, 0.59; 95% CI, 0.36-0.97; P = .04). Centres with a high volume of MMC cases significantly excised by MMS vs. WLE (odds ratio, 1.99; 95% CI, 1.63-2.44; P < .001). MMS was linked to improved survival for patients with T1/T2 MMC compared to other surgical modalities (WLE and narrow-margin excision).

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Merkel cell carcinoma (MCC)mohs micrographic surgery (MMS)wide local excision
Previous Post

Direct dispensation of free prenatal supplements improves outcomes in underserved communities

Next Post

2 Minute Medicine Rewind September 11, 2023

RelatedReports

Key predictors of recurrence and survival for Merkel Cell Carcinoma elucidated
Chronic Disease

Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma

September 21, 2023
Increased risk of non-melanoma skin cancer with subsequent keratinocytes carcinoma
Dermatology

Patient Perspective of Opioid Pain-Control Use After Mohs Micrographic Surgery

July 14, 2023
Melanoma immunohistochemical analysis useful to determine BRAFV600E mutation status
Dermatology

Narrow margin excision of T1a melanoma not associated with recurrence or melanoma-specific mortality

June 1, 2023
PD-1 blocker pembrolizumab may be a promising therapy for advanced Merkel-cell carcinoma
Chronic Disease

Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab

October 7, 2022
Next Post
Smoking during pregnancy associated with aerobic fitness of children

2 Minute Medicine Rewind September 11, 2023

High incidence of cognitive impairment associated with colorectal cancer

Religion and spirituality-based treatments are effective for mental health care

Prophylactic platelet transfusions prevent bleeding in hematologic cancers

Nivolumab/Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy
  • Methadone initiation linked to lower mortality compared to buprenorphine-naloxone after opioid overdose
  • Continuous femoral nerve block is not superior to continuous adductor canal block for postoperative pain following ACL reconstruction
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.

2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in